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Abstract The substitution, in the human V2 vasopressin
receptor, of the aspartate at position 136 by alanine leads to
agonist-independent activation of this mutant V2 receptor.
Pharmacological studies of the D136A V2 receptor helped us in
characterizing different V2 receptor antagonists. SR-121463A
and OPC-31260, two non-peptide antagonists, behaved as
inverse agonists, while two cyclic peptides d(CH2)5[D-Tyr(Et)
2,-
Val4,Tyr-NH2
9]AVP and d(CH2)5[D-Ile
2,Ile4,Tyr-NH2
9]AVP
known to be V2 antagonists, demonstrated clear partial agonist
properties. The finding of a constitutively activated human V2
receptor represents a useful tool in characterizing V2 receptor
antagonist ligands.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
In recent years, it has been shown that many G protein-
coupled receptors (GPCRs) may exist in an active form in the
absence of agonist [1,2]. This constitutive (or agonist-inde-
pendent) activity of GPCRs is now well documented and sev-
eral human diseases such as familial precocious puberty in
boys, hyperthyroidism and Janssen type chondrodysplasia
are associated with mutations inducing constitutive activation
of the corresponding receptor ^ e.g. LH, TSH and PTH/PTH-
related peptide [3^6]. A constitutive activity of others GPCRs
has also been reported for the K1B-adrenergic, K2-adrenergic,
the L2-adrenergic, the muscarinic cholinergic receptors, as well
as the AT1A angiotensin II, dopamine D5, 5-hydroxy-
tryptamine1A (5-HT1A), 5-HT1B, 5-HT1D, and 5-HT2C recep-
tors in cell lines in which they are overexpressed or mutated
[7^17]. In cells in which a constitutive receptor activity can be
measured, antagonists that reduce the levels of activity and
functional response are referred to as inverse agonists or an-
tagonists with negative intrinsic activity, whereas antagonists
that do not reduce activity are called neutral antagonists or
antagonists with no intrinsic activity [18].
The vasopressin V2 receptor belongs to the large family of
the GPCRs and is responsible for the antidiuretic e¡ect of the
neurohypophyseal hormone arginine vasopressin (AVP). The
binding of AVP to the V2 receptor, located on the basolateral
membrane of the principal cells of the renal collecting duct,
represents the ¢rst step of the antidiuretic action of this hor-
mone, activating adenylyl cyclase and then increasing the in-
tracellular concentration of cyclic adenosine monophosphate
(cAMP) [19]. This preliminary step initiates a cascade of intra-
cellular events that lead to the exocytic insertion of speci¢c
water channels, aquaporin 2, into the luminal membrane of
the renal principal cells [20].
Several di¡erent mutations in the V2 receptor gene have
been reported to be responsible for the loss of function or
dysregulation of the V2 receptor in patients with X-linked
congenital nephrogenic diabetes insipidus, a disease character-
ized by resistance of the renal collecting duct to the antidiu-
retic action of AVP [21], but to date no mutation responsible
for a gain of function ^ i.e. constitutive activity ^ of the V2
receptor has been described, either in vivo or in vitro.
The main goal of our study was to ¢nd out whether such a
constitutively active mutant V2 receptor may exist in vitro
and, if so, to use this mutant as a tool for a better character-
ization of di¡erent V2 receptor antagonists. Antagonists of the
V2 receptor, also called aquaretic agents, are of signi¢cant
clinical interest in several diseases characterized by an abnor-
mal increase of circulating AVP plasma levels leading to the
activation of the V2 receptors, responsible for water retention
and subsequent hypotonic hyponatremia (syndrome of inap-
propriate antidiuretic hormone secretion, liver cirrhosis, neph-
rotic syndrome, certain stages of congestive heart failure or
hypertension) [22^25].
Intact and broken cell preparations of COS-7 cells express-
ing a mutated human V2 receptor were used as our experi-
mental model. We demonstrate that a speci¢c mutation of
aspartate 136 in the human V2 receptor (Fig. 1), which be-
longs to the highly conserved DRH/Y sequence, causes its
constitutive activity. Evidence is also presented that certain
V2 receptor antagonists have a partial agonist activity on
the D136A mutant V2 receptor whereas others behave as in-
verse agonists.
2. Materials and methods
2.1. Drugs
AVP was from Bachem. The V2 receptor cyclic peptide antagonist
ligands d(CH2)5[D-Tyr(Et)2,Val4,Tyr-NH29]AVP and d(CH2)5[D-Ile2,
Ile4,Tyr-NH29]AVP were synthesized in the laboratory of Dr. M.
Manning (MCO, Toledo, OH). SR-121463A and OPC-31260 was
from Sano¢ Recherche. [3H]AVP (60^80 Ci/mmol) was from NEN
Life Science Products.
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2.2. DNA construct
The cloning of the human V2 receptor cDNA was performed as
previously described [26]. The cDNA was then subcloned into the
EcoRI/XbaI restriction sites of the eukaryotic expression vector
pCMV [27]. The sequence of the human V2 vasopressin receptor
cDNA was veri¢ed by direct dideoxynucleotide sequencing of both
strands (T7 sequencing kit, Pharmacia Biotech).
The D136A mutation was introduced in the human V2 vasopressin
receptor cDNA sequence directly on the eukaryotic expression vector
pCMV with the QuickChange site-directed mutagenesis kit (Strata-
gene) and its identity con¢rmed by direct dideoxynucleotide sequenc-
ing (T7 sequencing kit, Pharmacia). The supercoiled DNA used for
transfection was prepared with Qiagen columns (Qiagen, Chatsworth,
CA).
2.3. Cell culture and transient expression
Expression vectors harboring the wild type or mutant receptors
were transiently transfected into COS-7 cells (American Type Culture
Collection) by electroporation. COS-7 cells were grown in Dulbecco’s
modi¢ed Eagle’s medium (DMEM, Gibco BRL) supplemented with
10% fetal calf serum (Eurobio, France), 100 IU/ml penicillin and
streptomycin (Gibco BRL), in 5% CO2 in air at 37‡C. Electroporation
(280 V, 950 mF, Bio-Rad gene pulser electroporator) was performed
in a total volume of 300 Wl, with 20 Wg of carrier DNA (vector with-
out insert). Various amounts of plasmid DNA (vector with a sub-
cloned insert) ranging from 10 to 800 ng for the wild type V2 receptor
and from 25 ng to 2000 ng for the D136A mutant V2 receptor were
added, as well as 107 cells in electroporation bu¡er (50 mM K2HPO4,
20 mM CH3COOK, 20 mM KOH, pH 7.4). After electroporation,
cells were split into 24-well clusters for determination of cAMP accu-
mulation or for binding assays to intact cells.
2.4. Binding assays
Binding assays were performed either on intact cells or on cell
membranes.
2.4.1. Binding assays to intact cells. After electroporation, cells
were plated in 24-well clusters at a density of 2U105 cells/well. Bind-
ing assays were performed after 48 h. Cells were washed three times in
phosphate-bu¡ered saline (PBS), after which each well received 0.2 ml
of ice-cold PBS with 1% BSA and phenylalanine 1033 M and the
appropriate dilution of [3H]AVP. Plates were incubated for 4 h in
the cold room before removal of the binding mixture by aspiration.
After quickly rinsing four times with ice-cold PBS, 0.5 ml of 0.1 N
NaOH was added to each well to extract radioactivity. The £uid from
the well was then transferred to scintillation vials after neutralization
with 0.5 ml HCl 0.1 N. Non-speci¢c binding was determined under
the same condition in the presence of 0.5 mM unlabeled AVP. The
number of cells in each well was determined after trypsinization to
normalize the results as binding capacity per million cells (fmol/mil-
lion cells). All assays were performed in triplicate on at least three
separate batches of electroporated cells.
2.4.2. Binding assays on cell membranes. Binding experiments were
performed on COS-7 cell membrane preparations as previously de-
scribed [28]. For saturation experiments, [3H]AVP was used as the
radioligand; membrane protein (20^30 Wg) was incubated for 30
min at 30‡C with 1^2 nM [3H]AVP, a concentration equalling the
Kd value determined in the saturation experiments, and a concentra-
tion range of unlabeled ligands (10311 to 1035) for competition experi-
ments. In each set of experiments, non-speci¢c binding was deter-
mined in the presence of a 250^1000-fold excess of unlabeled ligand.
Bound and free radioactivity were separated by ¢ltration over What-
man GF/C ¢lters presoaked with 10 mg/ml of BSA. All assays were
performed in triplicate on at least three separate batches of electro-
porated cells.
The ligand binding data were analyzed by non-linear least-squares
regression using the computer program LIGAND [29].
2.5. cAMP assays
Transfected cells were plated in supplemented DMEM using 24-well
clusters and [3H]adenine (Isotopchim) was added to the culture me-
dium at a ¢nal concentration of 2 mCi/ml for the last day of culture
(36 h after cell electroporation). Cells were washed twice in PBS, then
PBS supplemented with glucose 5.5 mM and isobutylmethylxanthine
1 mM was added for 15 min. AVP (at concentrations ranging from
10312 to 1035 M) or the V2 receptor antagonists, SR-121463A [30],
OPC-31260 [31], d(CH2)5[D-Tyr(Et)2,Val4,Tyr-NH29]AVP [32] and
d(CH2)5[D-Ile2,Ile4,Tyr-NH29]AVP [33] were added to the medium.
After a further 10 min incubation period, the reaction was stopped
by replacing the incubation medium with 1 ml of 5% trichloroacetic
acid. ATP and cAMP were added in the acid extract at a concentra-
tion of 0.5 mM. Relative intracellular cAMP levels were determined
by measuring the formation of [3H]cAMP from the prelabeled adenine
nucleotide pool. Labeled cAMP was separated by sequential chroma-
tography on Dowex and alumina columns as previously described
[34]. The radioactivity present in the cAMP fractions was expressed
as a percentage of the sum of the radioactivity recovered in the cAMP
fraction and the radioactivity which was not retained by the Dowex
column. The latter mainly correspond to labeled ATP. All assays were
performed in triplicate on at least three separate batches of electro-
porated cells. The data were analyzed by means of non-linear regres-
sion using a sigmoidal dose-response equation (KaleidaGraph soft-
ware).
3. Results
We ¢rst mutated aspartate 136 of the DRH motif, which is
highly conserved in GPCRs, to an alanine mutant. Then the
wild type and the aspartate to alanine mutant (D136A) of the
human V2 receptor (Fig. 1), which mimics the situation found
in constitutively activated K1B-adrenergic receptor [8], were
transfected into monkey kidney COS-7 cells for binding and
cAMP assays. Receptor expression levels were studied by us-
ing increasing concentrations of cDNA encoding the D136A
mutant V2 receptor or the wild type V2 receptor during se-
quential electroporation procedures. COS-7 cells were trans-
fected with 10^800 ng cDNA/107 cells for the wild type and
with 50^2000 ng cDNA/107 cells for the D136A mutant V2
receptor and the receptor density was measured by binding
assay of [3H]AVP to intact cells (Fig. 2). For each value of
cDNA used for both receptors, binding and cAMP assays
were performed on transfected cells obtained during the
same electroporation procedure.
Analysis of the data obtained for the wild type V2 receptor
demonstrated that the receptor density was positively corre-
lated with the amount of cDNA used for transfection (Fig. 2).
For the D136A V2 receptor, the expression remained low and
signi¢cantly higher levels of expression could not be achieved
even using larger amounts of transfected cDNA (Fig. 2).
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Fig. 1. Schematic representation of the human V2 receptor showing
the primary sequence and the possible transmembrane topology
with the localization of the D136A mutation. The limits of the sev-
en transmembrane domains correspond to the alignment of the sev-
en putative transmembrane domains of vasopressin receptors pub-
lished by Mouillac [21,28].
D. Morin et al./FEBS Letters 441 (1998) 470^475 471
Comparable levels of receptor expression were obtained
with 15 ng cDNA/107 cells for the wild type and 2000 ng
cDNA/107 cells for the D136A mutant receptor. In these con-
ditions, the D136A and the wild type V2 receptors bound
AVP with an equivalent Kd (0.4 þ 0.27 nM and 0.57 þ 0.24
nM for the mutant and the wild type V2 receptor, respec-
tively) (Table 1). However, at this same level of expression,
the basal cAMP production was found to be signi¢cantly in-
creased (5^6-fold higher) for the D136A V2 receptor when
compared with the wild type V2 receptor demonstrating that
this mutant receptor is constitutively active (Fig. 3). For the
wild type receptor, the basal cAMP production was not de-
pendent on the receptor density and remained stable in spite
of a signi¢cant increase in the receptor expression, up to 7500
fmol/106 cells. In contrast, within the range of cDNA used,
the constitutive activity of the mutant receptor was always
linearly dependent on receptor density and did not show
any trend for saturation (Fig. 3).
Fig. 4 shows that the D136A V2 receptor retained its ability
to respond to the agonist and the EC50 value for adenylyl
cyclase stimulation by AVP for the COS-7 cells expressing
both receptors was not signi¢cantly modi¢ed (0.5 þ 0.15 nM
and 0.7 þ 0.1 nM for the mutant and the wild type V2 recep-
tor, respectively). However, the cAMP production induced by
1036 M AVP added on COS-7 cells expressing the same
amount of receptors was found to be 3-fold higher for the
D136A mutant than for the wild type V2 receptor (Fig. 4).
To better characterize the properties of di¡erent V2 receptor
antagonists, we used the constitutively activated mutant V2
receptor to study the e¡ects of this class of compounds on
the cAMP contents of intact COS-7 cells expressing the wild
type or the D136A V2 receptor. Two cyclic peptide antago-
nists d(CH2)5[D-Tyr(Et)2,Val4,Tyr-NH29]AVP and d(CH2)5[D-
Ile2,Ile4,Tyr-NH29]AVP and two non-peptide antagonists SR-
121463A and OPC-31260 were used in these assays. The ¢rst
two display a high [32] and a low [26] a⁄nity for the human
V2 receptor (Ki : 1.12 þ 0.1 nM and 128 þ 6 nM, respectively),
while the other two have a high and mild a⁄nity for the
human V2 receptor (Ki : 1.20 þ 0.11 nM and 36.3 þ 0.4 nM,
respectively) [30,31].
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Fig. 3. The e¡ect of expression level on basal level of cAMP pro-
duction in COS-7 cells expressing the wild type (E) and D136A (b)
V2 receptors. COS-7 cells were transfected with increasing amounts
of cDNA which ranged from 10 to 800 ng/107 cells for the wild
type and from 50 to 2000 ng/107 cells for D136A. The results are
from at least three independent experiments, each performed in trip-
licate.
Fig. 2. Receptor density measured in COS-7 cells expressing the
wild type (E) and D136A (b) V2 receptors transfected with increas-
ing amounts of cDNA which ranged from 10 to 800 ng/107 cells for
the wild type and from 50 to 2000 ng/107 cells for the D136A V2
receptors. The receptor density was measured during binding assays
to intact cells, using [3H]AVP. The results are from at least three in-
dependent experiments, each performed in triplicate.
Table 1
Pharmacological properties of the wild type and D136A constitutively active human V2 receptors: binding to AVP, cyclic peptide antagonists
and non-peptide antagonists
Kd (nM)
Wild type D136A
A: [3H]AVP 0.57 þ 0.24 0.40 þ 0.27
Ki (nM)
Wild type D136A
B: d(CH2)5[D-Ile2,Ile4,Tyr-NH29]AVP 128 þ 6 157 þ 79
d(CH2)5[D-Tyr(Et)2,Val4,Tyr-NH29]AVP 1.12 þ 0.1 1.72 þ 0.47
SR-121463A 1.2 þ 0.11 0.79 þ 0.18
OPC-31260 36.3 þ 0.4 50.8 þ 10
A: The Kd values for [3H]AVP were directly determined in saturation experiments. B: The Ki values for the unlabeled ligands were obtained in
competition binding assays by displacement of [3H]AVP (1^2 nM).
The binding assays were conducted on membrane preparations of COS-7 cells expressing the receptors. All values are the mean þ S.E.M. of three
di¡erent experiments each performed in triplicate.
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The a⁄nities of these di¡erent antagonists, measured by
competition experiments for both receptors, are summarized
in Table 1. It demonstrates that the Ki values of these com-
pounds for either the wild type or the D136A V2 receptor are
not statistically di¡erent. The e¡ects of these four compounds
on the cAMP production by COS-7 cells expressing the wild
type and the D136A mutant V2 receptors are given in Fig.
5A,B. It shows that the two cyclic peptide antagonists
d(CH2)5[D-Tyr(Et)2,Val4,Tyr-NH29]AVP and d(CH2)5[D-Ile2,
Ile4,Tyr-NH29]AVP behaved as partial agonists for the
D136A V2 receptor with a maximal activity of nearly 30%
of the response induced by 10 WM AVP. These partial agonist
properties were also found for the wild type V2 receptor but
with a much lower potency, the maximum cAMP production
being less than 5% of the response induced by 10 WM AVP.
Conversely, the non-peptide antagonist SR-121463A be-
haved as an inverse agonist. Indeed, increasing doses of this
compound progressively suppressed the basal cAMP produc-
tion of the constitutively active mutant receptor. OPC-31260,
the non-peptide antagonist, also decreased the basal cAMP
production of the mutant, but was found to be less potent
and e⁄cient than SR-121463. This may be related to the dif-
ference observed in the a⁄nity of the two compounds for this
mutant V2 receptor.
Thus, the data shown in Fig. 5 suggest that antagonists
with partial agonist activity and antagonists with inverse ago-
nist activity were distinguished by analysis of their action on
cAMP production by cells expressing the D136A V2 receptor.
4. Discussion
The two major ¢ndings of this study were that replacement
of aspartate 136 by alanine in the human V2 receptor results
in constitutive activation of the receptor with respect to
cAMP production, and that two classes of V2 receptor antag-
onists could be distinguished by their e¡ects on cAMP content
of intact COS-7 cells expressing a constitutively activated hu-
man mutant V2 receptor. The functional and pharmacological
characterization of the D136A V2 receptor demonstrated that,
for the ¢rst time, a mutant V2 receptor should be included in
the family of the constitutively active GPCRs mutant recep-
tors. These ¢ndings are in good agreement with those shown
previously for a similar mutation in the K1B-adrenergic recep-
tor [8] which is coupled to Gq-mediated stimulation of phos-
pholipase C. In this receptor, D142 was mutated into di¡erent
amino acids and the D142A K1B-adrenergic receptor exhibited
a signi¢cant constitutive activity.
We showed that the cAMP basal production was increased
5-fold when compared with the wild type V2 receptor, in sim-
ilar conditions of receptor expression. Analysis of the cAMP
production after stimulation by 1036 M AVP suggested that
the D136A V2 receptor behaves also as a superactive receptor,
demonstrating a 3-fold increase in cAMP production, when
compared with the wild type (Fig. 4). The constitutive activity
of the D136A V2 receptor was clearly receptor-mediated as
indicated by its dependence on the expression levels of the
receptor and its susceptibility to inhibition by the V2 receptor
antagonists SR-121463A and OPC-31260. In contrast to what
was observed previously for di¡erent constitutively active mu-
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Fig. 5. cAMP production in COS-7 cells expressing the wild type
(A) and the D136A (B) human V2 receptor. E¡ects of increasing
doses (10312 to 1036 M) on cAMP production of the non-peptide
antagonist compounds SR-121463A (F) [30] and OPC-31260 (a)
[31], and of the cyclic peptide antagonist ligands d(CH2)5[D-Tyr-
(Et)2,Val4,Tyr-NH29]AVP [32] (b) and d(CH2)5[D-Ile2,Ile4,Tyr-
NH29]AVP (O) [33]. The COS-7 cells were transfected with 15 ng
cDNA/107 cells for the wild type and 2000 ng/107 cells for the con-
stitutively active D136A V2 receptor to obtain similar receptor den-
sities. Each curve on graphs A and B is representative of at least
three independent experiments, each performed in triplicate.
Fig. 4. E¡ects of increasing doses (10312 to 1036 M) of AVP on
cAMP production in COS-7 cells expressing the wild type (F) and
D136A (a) human V2 receptors. COS-7 cells were transfected with
15 ng cDNA/107 cells for the wild type and 2000 ng/107 cells for
the constitutively active D136A V2 receptor. The receptor densities
measured on intact cells were 251 þ 47 and 298 þ 7 fmol/106 cells for
the wild type and D136A V2 receptors respectively. The results are
the means from at least three independent experiments, each per-
formed in triplicate.
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tant adrenergic receptors [35^38], the a⁄nity of the D136A V2
receptor for AVP binding was not signi¢cantly improved
when compared to the wild type V2 receptor.
The D136A V2 receptor, like other receptors mutated at
DRH/Y [8], displays a low expression level when expressed
in COS-7 cells. This lowered receptor density could be ex-
plained by the receptor down-regulation as a consequence of
constitutive activation. It may also be related to a structural
instability of the constitutively activated receptor, which ap-
pears more susceptible to denaturation [39]. By Western blot
analysis, we showed that the migration patterns for the wild
type and the D136A V2 receptor were similar suggesting that
the mature form of both receptors can be expressed at the cell
surface (data not shown). Of course, one cannot exclude that
a large portion of the mutated V2 receptor is retained in the
endoplasmic reticulum or in the Golgi complex, or is not fully
processed.
The mutated aspartate at position 136 of the human V2
receptor belongs to the DRH/Y sequence highly conserved
throughout the whole GPCR family. It has been proposed
by Scheer et al., from data concerning the constitutively active
D142A K1B-adrenergic receptor, that the prototropic equili-
brium between the deprotonated (anionic) and protonated
(neutral) forms of this aspartate residue of the DRY motif
seems to play a key role in the molecular events leading to
its agonist-independent activation [8]. In our work, we showed
that the replacement of the corresponding residue in the V2
receptor, i.e. the aspartate in position 136, with the non-polar
amino acid alanine also confers a constitutive activity to the
V2 receptor. Therefore, our data show that, if the molecular
events accompanying the structural modi¢cation in constitu-
tively active GPCRs remain largely unknown, some conclu-
sions drawn from di¡erent GPCRs are, at least partly, repro-
ducible from one type to another. From our ¢ndings, as we
failed to ¢nd any signi¢cant changes in the binding a⁄nity of
the D136A V2 receptor for the agonist, it is also suggested
that for the V2 receptor, the conformational link between
receptor domains involved in ligand binding and the DRH
sequence is di¡erent than for other GPCRs, i.e. an activating
mutation at the DRH site does not have an e¡ect on the
ligand binding domain.
The observation that a number of GPCRs can be sponta-
neously active has led to a simple model in which receptors
exist in an equilibrium between inactive, R, and active, R*,
conformation states, knowing that in the absence of agonist
and in basal conditions, the equilibrium between the two
states markedly favors R over R*. The results of our experi-
ments can also be interpreted with this model. The pharma-
cological study of the di¡erent compounds used demonstrated
clearly that SR-121463A, which is known to be a human V2
receptor antagonist, behaved as an inverse agonist. OPC-
31260, another human V2 receptor antagonist, also demon-
strated inverse agonist properties. The discrepancies observed
between these non-peptide antagonists and the two cyclic pep-
tide antagonists studied demonstrated that the molecular in-
teractions between these two classes of antagonists com-
pounds and the V2 vasopressin receptor are necessarily
di¡erent. If the inverse agonists are thought to bind the in-
active form of the receptor preferentially and then shift the
equilibrium toward R suppressing the constitutive activity, the
two peptide ligands, d(CH2)5[D-Tyr(Et)2,Val4,Tyr-NH29]AVP
and d(CH2)5[D-Ile2,Ile4,Tyr-NH29]AVP, which have a cyclic
structure close to AVP and behave as partial agonists on
the D136A mutant V2 receptor, seem to bind preferentially
the active form of the receptor, R*, as agonist ligands do.
It is worth noting at this point that the antagonist
desGly-d(CH2)5[D-Tyr(Et)2,Val4]AVP [23], which acts as an
aquaretic in the rat, was found to have agonist (antidiuretic)
properties when tested in man [25]. The D136A V2 receptor
clearly shows in vitro this property that was otherwise di⁄cult
to observe and appears to be a useful tool to characterize the
di¡erent human V2 receptor antagonists which are thought to
be promising therapeutic agents in several pathological con-
ditions.
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